Premium
Noradrenaline and 5‐hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.
Author(s) -
Jenner P.,
Sheehy M.,
Marsden CD
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb05876.x
Subject(s) - dopamine , parkinson's disease , forebrain , neuroscience , medicine , 5 ht receptor , endocrinology , neurotransmitter , serotonin , norepinephrine , psychology , disease , central nervous system , receptor
1 Dopamine deficiency in the brain is the prime biochemical deficit in Parkinson's disease, but loss of noradrenaline and 5HT also may contribute. 2 In rats, 5HT‐containing neurones originating from the dorsal and median raphe nuclei innervate forebrain dopamine‐containing areas so as to impose an inhibitory regulatory tone on dopamine function. However, this interaction between brain dopamine and 5HT‐ containing neuronal systems is complex, and the effect produced appears dependent on the relative activity of each system. 3 Anatomical evidence for innervation of dopamine‐containing brain regions by noradrenaline fibres in the rat is scanty, but functional studies suggest the existence of inputs which facilitate dopamine function. 4 Drug therapy designed to increase or decrease brain 5HT function has had no consistent effect in Parkinson's disease. 5 Manipulation of brain noradrenergic activity in Parkinson's disease had little effect, although the noradrenaline precursor L‐threo‐DOPS may reduce freezing attacks. 6 Until more specific drug molecules are available the role of brain noradrenergic and 5HT mechanisms in Parkinson's disease remains uncertain.